In the kidney, immunoglobulin light chain amyloidosis (AL) can be deposited in vascular-limited AL (V-AL) or diffuse (D-AL) pattern. These patterns are associated with different clinical presentations. A nested case study was performed to describe these differences. V-AL was defined by the vascular-limited deposits. Cases were matched for age, sex and date of renal biopsy. There were 12 cases of V-AL (mean age 61 6 11 years) and 24 cases of D-AL. Median follow-up was 26 months for V-AL and 38 months for D-AL, P ¼ 0.14. Lambda was more common in D-AL (83.3%) than V-AL (50%, P ¼ 0.04). Cardiac function was similar between the two groups. V-AL patients presented with lower renal function (serum creatinine ¼ 2.1 versus 1.3 mg/dL, P ¼ 0.02; estimated glomerular filtration rate 31 versus 59 mL/min/1. 6 months, log-rank P ¼ 0.02). Our study found that V-AL patients presented with more severe renal insufficiency and less proteinuria than D-AL. There was a preference for k light chain in the D-AL that was not noted in the V-AL. Patients with D-AL in this study had a longer median survival but most of them were stem cell transplantation candidates.
Introduction
Amyloidosis represents a group of diseases characterized by protein misfolding and the extracellular deposition of the resultant b-sheet fibrils [1] . These fibrils have the unique ability to absorb Congo red dye and give off an apple-green birefringence when viewed under polarized light. In industrialized countries, monoclonal immunoglobulin light chain amyloidosis (AL) is the most common form, which is the sequela of a plasma cell dyscrasia [2] . The kidney is the most frequently affected organ. In a study of 474 patients, 73% presented with proteinuria and nearly half with renal insufficiency [3] . In a separate study of 145 patients, end-stage renal disease (ESRD) was much more common in those who presented with renal manifestations than those without (42 versus 5%) [4] . A recent Italian study of biopsy-proven renal AL patients showed a similar rate (39%) of ESRD and median survival on dialysis [5] . Life expectancy after initiation of dialysis was short with a median survival of 10.4 months with 20% dying within the first month of initiating dialysis.
Since renal manifestations are so common in AL, the diagnosis is often made by renal biopsy [6] . On light microscopy, amyloid is identified as an amorphous eosinophilic material that is weakly positive to negative on periodic acid Schiff stain and typically negative on silver methenamine stain. All types of amyloid demonstrate apple-green birefringence when viewed under polarized light after Congo red staining and the fibrils have an average diameter of 8-12 nm. In most cases, the mesangium is the first place where amyloid deposition occurs. In more advanced cases, amyloid deposits can be seen throughout the glomeruli, interstitium and vascular compartments. AL amyloidosis is diagnosed by demonstrating light chain restriction by immunofluorescence staining or immunohistochemistry in the amyloid deposits. In rare cases, the deposits may be vascular limited [7] . The vascular-limited deposition has been described in AA (serum amyloid A) but little has been reported about this pattern in AL [8, 9] . The aim of this study is to compare the clinical features of patients with vascular-limited AL (V-AL) versus those with diffuse renal involvement (D-AL).
Materials and methods
This study was approved by the Institutional Review Board at the Mayo Foundation in accordance with the Declaration of Helsinki and the Health Insurance Portability and Accountability Act guidelines. The Renal Biopsy Database at Mayo Clinic from July 1994 to November 2009 was queried for diagnosis of amyloidosis. Of the 316 renal biopsies with amyloidosis, 234 were found to be AL. Amyloidosis was diagnosed by Congo red stain and electron microscopy. Immunofluorescence staining with antibody to IgG, IgM, IgA, C1q, C3, C4, j and k free light chain (FLC), albumin and fibrinogen was performed on all biopsys. If in conclusive, immunoperoxidase staining was performed on paraffin-embedded tissue sections for serum amyloid P, serum amyloid A, j and k FLC, albumin, prealbumin and b-2 microglobulin. AL was diagnosed by the demonstration of selective j or k staining of the amyloid by immunofluorescence (n ¼ 31) or immunohistochemistry (n ¼ 5). Cases of amyloidosis other than AL were excluded. V-AL was defined by the presence of amyloid deposits in renal vessels and the absence of deposits in the glomeruli or tubulointerstitial compartment.
Clinical data were collected via the electronic and paper medical records. Parameters include age, sex, weight (kilogram), systolic blood pressure (SBP), diastolic blood pressure (DBP) at baseline and at last follow-up. In addition, echocardiogram and bone marrow biopsy findings were obtained. Laboratory data collected included serum creatinine (Scr), troponin T (c-TnT), N-terminal pro-brain natriuretic peptide (NTpro-BNP), M spike (grams per deciliter), serum FLC, creatinine clearance (CrCl), estimated glomerular filtration rate (eGFR), urine immunofixation and proteinuria. Treatments received for AL were also recorded. Kappa or lambda subtype was determined by serum immunofixation, serum FLC ratio (when available) and the light chain restriction on the biopsy.
For every V-AL under study, two D-AL patients were selected matched for age, sex and date of renal biopsy. Median (range) was used for data that did not show a Gaussian distribution. Statistical calculations were performed using JMP software package version 8.0 (SAS Institute Inc., Cary, NC). Pearson's chi-square tests were performed on categorical data. Comparison of continuous variables was performed with analysis of variance and Wilcoxon rank-sum tests. All statistics were performed using JMP software, version 8.0 (Cary, NC). P <0.05 was considered significant.
Results
Twelve or 5.1% of the total cases had only vascular-limited renal amyloidosis. Twenty-four controls were selected for age, sex and date of biopsy match. Their mean age at baseline was 57 (range 46-79) years. Males outnumbered females 2:1. The median follow-up was 26 (0-63) months for V-AL and 38 (0-110) months for D-AL, P ¼ 0.14. Of the 36 patients, 3 patients (8.3%) had diabetes, 2 patients had hypothyroidism, 2 patients had solid tumors. Seven patients (20.6%) had multiple myeloma. No significant differences were found in the comorbidities between the two groups.
Hematologic parameters
In the V-AL patients, the distribution of j and k was 50:50. However, in patients with D-AL, there was a preference toward k light chain with 83.3% having a k monoclonal light chain, P ¼ 0.04. In patients with V-AL, one had a monoclonal IgAk, two-IgGj and five-IgGk. In the D-AL group, three had monoclonal IgAk, one-IgDk, three-IgGj, eight-IgGk and three monoclonal k. Serum monoclonal protein studies (serum protein electrophoresis and immunofixation) were negative in one V-AL and six of the D-AL patients. One patient in each group had a negative urine monoclonal protein study by urine protein electrophoresis and immunofixation. The median bone marrow plasma cell percentage was 8% (1.8-31%) in V-AL and 5% (1-30%) in D-AL, P ¼ 0.06. Plasma cell labeling index was 0% for both groups, P ¼ 0.5. There was a trend toward higher FLC levels in the D-AL but this was not statistically significant. In the j patients, the median j FLC was 16.4 (1.3-146) mg/dL in V-AL patients and 37.7 (3.1-270) mg/ dL in the D-AL, P ¼ 0.48. In the k patients, the median k FLC was 4.5 (1.8-20.3) mg/dL in the V-AL and 11.0 (3.1-58.7) mg/dL in the D-AL, P ¼ 0.37. The reference range for j FLC was 0.33-1.94 mg/dL, k FLC was 0.57-2.63 mg/dL and j:k ratio was 0.26:1.65.
Fat aspirate was positive in 60% of V-AL and 59% of D-AL patients who had the procedure performed, P ¼ 0.96. In addition, five V-AL patients underwent other tissue biopsies. Amyloid deposits were found in the heart (2 of 3 cases), colon (2 of 3 cases), duodenum (1 of 2 cases), esophagus (0 of 1 case), gastric antrum (1 of 1 case), liver (0 of 1 case), infraorbital tissue (0 of 1 case) and thyroid (1 of 1 case). An autopsy report was available for one V-AL patient. Amyloid deposits were found in the heart (four chambers, valves, intramural vessels, epicardium and endocardium), lungs (vascular and alveolar deposists), spleen (sinusoidal deposits), liver (arterial and portal deposits), pancreas (vascular and mild interstitial deposists), GI tract (mucosal and vascular deposits) and kidneys (vascular deposits).
Cardiac parameters
Echocardiographic findings (EF) were similar between the two groups. The median EF% for V-AL patients was 63 
Renal parameters
No differences were noted in baseline blood pressure between the two groups. V-AL patients showed a mean baseline SBP of 115.5 AE 24. 
Treatment and outcomes
Melphalan 1 prednisone was the treatment of choice in 31.3% of the patients, followed by dexamethasone alone (12.5%), melphalan 1 dexamethasone (6.25%), and 3.13% of patients received melphalan 1 thalidomide 1 dexamethasone, melphalan 1 bortezomib 1 dexamethasone, melphalan 1 lenalidomide 1 dexamethasone, melphalan 1 prednisone 1 bortezomib, melphalan 1 prednisone 1 lena- found in the renal outcome between both groups. There was, however, significant difference in terms of patient survival. Median survival was 77.2 months in patients with D-AL versus 40.6 months in V-AL patients ( Figure 3 , P ¼ 0.02).
At the time of the study, nine patients had died from each group, P ¼ 0.03.
Discussion
Traditionally, renal amyloidosis is associated with massive proteinuria and renal insufficiency. In a large population of AL patients, the median 24-h urine protein excretion was found to be 1.2 g/day but 36% had >3 g/day and 20% had >6 g/day [3] . Despite the common presence of proteinuria, the lack of proteinuria does not predict the absence of renal involvement. In some patients, renal amyloidosis can present with renal insufficiency without significant proteinuria. This in fact has been well described in patients with AA amyloidosis where the amyloid deposits are predominantly limited to the vessel walls [8] [9] [10] . The prevalence of vascular-limited renal amyloidosis ranges from 12.5 to 28.9% in AA amyloidosis. In one study, only proteinuria was noted to be different between the vascular-limited AA patients and glomerular AA patients [8] . In another study, significant differences were noted in both proteinuria and renal function. Patients with vascular-limited deposits had lower proteinuria (1.4 g/day) and lower CrCl (33 mL/min) as compared to those with glomerular deposits (4.9 g/day and 52 mL/min, respectively). However, arteriolar deposit was not the only factor associated with further decrease in renal function. The amount of amyloid deposited in the glomeruli and the degree of interstitial fibrosis and tubular atrophy also seem to play a role in future deterioration of renal function [10] . Finally, one study with a 5-year follow-up again showed no difference in proteinuria at the time of entry into the study but significant differences in proteinuria occurred during follow-up between the patients with glomerular deposits (2.2 g/day) versus those with vascular-limited deposits (0.05 g/day, P < 0.001). This study also showed that while both vascular-limited AA patients and glomerular AA patients had elevated Scr at the time of presentation, only those with glomerular involvement had progression of renal insufficiency [9] . The better renal prognosis in the patients with vascular AA involvement in this study seems to confirm observations made by others. In contrast to AA, little is known about vascular-limited renal amyloidosis in AL patients. There are similarities between V-AL and the vascular-limited AA patients. Both groups have significantly lower proteinuria than the patients with glomerular deposits in both types of amyloidosis. The highest level of proteinuria in this study was 1 g/day in contrast to 22 g/day in the D-AL group. Renal function was significantly lower at diagnosis in the V-AL as compared to the D-AL, which was similar to the AA patients with vascular-limited amyloid deposits [9, 10] . However, unlike the AA patients, the D-AL in our study did not have a worse renal prognosis as compared to the V-AL. Moreover, the overall prognosis was actually much worse for the V-AL in this study than the D-AL. The reason for this remains unclear. It is possible that the lack of proteinuria and features of nephrotic syndrome in patients with V-AL may cause delay in diagnosis resulting in more advanced disease. We had tried to avoid the influence of potential differences in treatment by matching the time of diagnosis during the nested case study. There were no significant differences in terms of treatment received between the two groups of patients. The disparity in mortality is even more interesting when one considers that cardiac involvement was similar between the two groups at the time of diagnosis as best we can tell.
To the best of our knowledge, this study represents the largest cohort of vascular-limited renal AL patients. The results of this study show that similar to AA, AL can involve the kidney without significant proteinuria with the only presenting sign being an elevated Scr and decreased eGFR. It is important to recognize this and AL should be in the differential diagnosis when seeing a patient with unexplained renal failure without proteinuria. Monoclonal protein studies from both serum and urine should be performed since neither is 100% sensitive. If either is positive, a renal biopsy should be performed even if the patient has no or little proteinuria. Early referral to an amyloid center would be beneficial as these patients may have a poorer prognosis. Further studies are warranted to better understand the difference in prognosis and to try to determine if different treatment options are needed for the vascular-limited patients.
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